RICS:HNSA.ST

Hansa Biopharma and Genethon announce collaboration to develop imlifidase as pre-treatment to gene therapy in Crigler-Najjar syndrome patients with anti-AAV antibodies

Retrieved on: 
Thursday, April 27, 2023

The presence of circulating NAbs today excludes patients from entering clinical studies with potentially curative gene therapy treatments and from future access to approved gene therapies.

Key Points: 
  • The presence of circulating NAbs today excludes patients from entering clinical studies with potentially curative gene therapy treatments and from future access to approved gene therapies.
  • This research collaboration further validates Hansa's commitment in gene therapy and underscores the important role that our antibody-cleaving enzyme technology can play in ensuring that even more patients can benefit from life-saving gene therapies".
  • Through the collaboration announced today, patients with Crigler-Najjar and pre-formed antibodies to AAV8 will be enrolled in a study with similar design where imlifidase is evaluated as a pre-treatment to enable gene therapy treatment with GNT-0003.
  • Crigler-Najjar syndrome is an ultra-rare disease affecting less than one case per one million people per year.1
    Frédéric Revah, CEO, Genethon added: "Patients with pre-existing neutralizing antibodies against AAV vectors cannot today benefit from gene therapy.

Hansa Biopharma interim report January-March 2023

Retrieved on: 
Thursday, April 20, 2023

Søren Tulstrup, President and CEO of Hansa Biopharma, comments

Key Points: 
  • Søren Tulstrup, President and CEO of Hansa Biopharma, comments
    "Hansa's commercial efforts for Idefirix® in Europe continue to progress as planned.
  • H1 2023            Anti-GBM Phase 3: First patient enrolled
    H2 2023            Long-term follow-up study in kidney transplantation: 5-year data readout
    H2 2023            AMR Phase 2: Full data readout
    H2 2023            GBS Phase 2: First data readout
    Hansa Biopharma will host a telephone conference today Thursday April 20, 2023, 14:00 CET / 8:00am EST.
  • The presentation will be held in English and be hosted by Hansa Biopharma's CEO, Søren Tulstrup, and CFO, Donato Spota.
  • To participate in the telephone conference, please use the dial-in details provided below:
    The interim report and latest investor presentation can be downloaded from our web:
    Investor road show presentation Q1, 2023 https://www.hansabiopharma.com/investors/presentations/
    This is information that Hansa Biopharma AB is obliged to make public pursuant to the Securities Markets Act.

Hansa Biopharma to host conference call to provide interim results for January-March 2023 and a Business Update

Retrieved on: 
Friday, April 14, 2023

LUND, Sweden, April 14, 2023 /PRNewswire/ -- Hansa Biopharma AB (Nasdaq Stockholm: HNSA) will publish its interim report for January-March 2023 at 8:00 CET on April 20, 2023.

Key Points: 
  • LUND, Sweden, April 14, 2023 /PRNewswire/ -- Hansa Biopharma AB (Nasdaq Stockholm: HNSA) will publish its interim report for January-March 2023 at 8:00 CET on April 20, 2023.
  • All interested parties are invited to participate in a telephone conference, which will include a presentation of the year-end results and a business update, on the same date at 14:00 CET/8:00am EST.
  • The event will be hosted by Hansa Biopharma's CEO, Søren Tulstrup, and CFO, Donato Spota, and the presentation will be held in English.
  • Link to presentation
    To participate in the telephone conference, please use the dial-in details provided below:
    April 25, 2023    Van Lanschot Kempen Life Sciences Conference 2023, Amsterdam
    May 11, 2023 Erik Penser Company Day, Malmö
    May 25, 2023    Erik Penser Company Day, Stockholm
    Aug 24, 2023    Erik Penser Company Day, Stockholm
    Sept 7, 2023    CITI Annual BioPharma Conference, Boston
    Sept 11, 2023    MorganStanley Global Healthcare Conference, NYC
    Sept 14, 2023    Pareto Annual Healthcare Conference, Stockholm
    Nov 22, 2023    Ökonomisk Ugebrev Life Science Event, Copenhagen

Hansa Biopharma announces positive reimbursement decision in Spain for Idefirix® (imlifidase) as desensitization treatment for highly sensitized patients in kidney transplantation

Retrieved on: 
Wednesday, March 29, 2023

The reimbursement approval of Idefirix® in Spain is another important step in this direction, as it now allows highly sensitized patients to be desensitized using Idefirix®, enabling a potentially lifesaving kidney transplant."

Key Points: 
  • The reimbursement approval of Idefirix® in Spain is another important step in this direction, as it now allows highly sensitized patients to be desensitized using Idefirix®, enabling a potentially lifesaving kidney transplant."
  • Of almost 4000 patients registered on the waiting list for a kidney transplant in Spain at the end of 20212, up to one in five (20%)3 are classified as highly sensitized.
  • "Many highly sensitized patients are still disadvantaged and in urgent need of more personalized and innovative desensitization options that can enable incompatible kidney transplantation.
  • This is information that Hansa Biopharma AB is obliged to make public pursuant to the EU Market Abuse Regulation.

Matthew Shaulis appointed Chief Commercial Officer and US President of Hansa Biopharma

Retrieved on: 
Friday, March 3, 2023

LUND, Sweden, March 3, 2023 /PRNewswire/ -- Hansa Biopharma, "Hansa" (NASDAQ Stockholm: HNSA), a pioneer in enzyme technology for rare immunological conditions, announced today that Matthew Shaulis will join the company effective 16 March as Chief Commercial Officer and President of the U.S. affiliate, Hansa Biopharma, Inc.

Key Points: 
  • LUND, Sweden, March 3, 2023 /PRNewswire/ -- Hansa Biopharma, "Hansa" (NASDAQ Stockholm: HNSA), a pioneer in enzyme technology for rare immunological conditions, announced today that Matthew Shaulis will join the company effective 16 March as Chief Commercial Officer and President of the U.S. affiliate, Hansa Biopharma, Inc.
  • He will report to President and CEO Søren Tulstrup and join the Executive Committee.
  • I would like to thank and congratulate Henk Doude van Troostwijk, who is moving into a new role as Vice President, Commercial Excellence, for his many contributions."
  • I'm looking forward to partnering across the enterprise to build out the U.S. organization and advance the global commercial priorities."

Hansa Biopharma announces positive reimbursement decision for Idefirix® (imlifidase) in the Czech Republic

Retrieved on: 
Monday, January 2, 2023

"We are very pleased to see that Idefirix® is now reimbursed in the Czech Republic for the treatment of highly sensitized kidney patients.

Key Points: 
  • "We are very pleased to see that Idefirix® is now reimbursed in the Czech Republic for the treatment of highly sensitized kidney patients.
  • These patients have a serious disease burden and unmet needs and this decision is a significant milestone for them", says Søren Tulstrup, President and CEO, Hansa Biopharma.
  • "For Hansa, this decision is well aligned with  our vision: A world where patients with rare immunologic diseases can lead long and healthy lives."
  • Hansa Biopharma is based in Lund, Sweden, and has operations in Europe and the U.S.

Hansa Biopharma announces positive reimbursement decision in Italy for Idefirix® (imlifidase) as desensitization treatment for highly sensitized patients in kidney transplantation

Retrieved on: 
Thursday, December 8, 2022

The decision by the Italian Medicine Agency (AIFA) provides highly sensitized patients in Italy with the opportunity to receive Idefirix to enable kidney transplantation.

Key Points: 
  • The decision by the Italian Medicine Agency (AIFA) provides highly sensitized patients in Italy with the opportunity to receive Idefirix to enable kidney transplantation.
  • By the time the body starts to synthesize new IgG, the patient will be receiving post transplant immunosuppressive therapy to reduce the risk of organ rejection.
  • Hansa Biopharma is a pioneering commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions.
  • Hansa has developed a first-in-class immunoglobulin G (IgG) antibody-cleaving enzyme therapy, which has been shown to enable kidney transplantation in highly sensitized patients.

Hansa Biopharma to host conference call to provide interim results for January-September 2022 and Business Update

Retrieved on: 
Friday, September 30, 2022

LUND, Sweden, Sept. 30, 2022 /PRNewswire/ -- Hansa Biopharma AB (NASDAQ Stockholm: HNSA) will publish its interim report for January-September 2022 at 8:00 CET on October 20, 2022.

Key Points: 
  • LUND, Sweden, Sept. 30, 2022 /PRNewswire/ -- Hansa Biopharma AB (NASDAQ Stockholm: HNSA) will publish its interim report for January-September 2022 at 8:00 CET on October 20, 2022.
  • All interested parties are invited to participate in a telephone conference, which will include a presentation of the interim results and a business update, on the same date at 14:00 CET/8:00am EST.
  • The event will be hosted by Hansa Biopharma's CEO, Sren Tulstrup, and CFO, Donato Spota, and the presentation will be held in English.
  • Hansa Biopharma is based in Lund, Sweden and has operations in Europe and the U.S.

Hansa Biopharma achieves Great Place to Work® certification for the third consecutive year

Retrieved on: 
Friday, September 30, 2022

Metrics related to trust in the company, credibility, pride and fairness, continue to be among those most highly rated by employees.

Key Points: 
  • Metrics related to trust in the company, credibility, pride and fairness, continue to be among those most highly rated by employees.
  • LUND, Sweden, Sept. 30, 2022 /PRNewswire/ --Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), the pioneer in enzyme technology for rare immunological conditions, today announced its certification as a Great Place to Work 2022, awarded by the Great Place to Work institute, an independent and globally recognized authority on workplace culture.
  • "We are very encouraged by this third consecutive certification of Hansa as a Great Place to Work.
  • Great Place to Work is the global authority on workplace culture.

The Scottish Medicines Consortium (SMC) recommends use of Hansa Biopharma's Idefirix[®] (imlifidase) as desensitization treatment for highly sensitized kidney transplant patients

Retrieved on: 
Monday, September 12, 2022

Kidney transplant candidates are classified as highly sensitized if they have a broad and intense range of pre-formed antibodies against almost all donororgans.

Key Points: 
  • Kidney transplant candidates are classified as highly sensitized if they have a broad and intense range of pre-formed antibodies against almost all donororgans.
  • It is fantastic to see that the SMC has followed the direction of England and Wales to offer certain highly sensitized patients the opportunity of a life-altering transplant.
  • "We are thrilled that the SMC has recommended Idefirixas the first licensed therapy for highly sensitized kidney patients in Scotland.
  • Hansa has developed a first-in-class immunoglobulin G (IgG) antibody-cleaving enzyme therapy, which has been shown to enable kidney transplantation in highly sensitized patients.